CasLoc logo
All Cases PTAB Litigations UPC Oppositions

Meda Pharmaceuticals Inc. v. Teva Pharmaceuticals USA, Inc.

1:15-cv-00785

Overview

Case Number 1:15-cv-00785
Filing Date 2015-09-08
Status Terminated
Termination Date 2017-07-28
Court District Court, D. Delaware (ded)
Nature of Suit 830 Patent
Jurisdiction Type Federal Question
Cause of Action 35:0145
Jury Demand None

Parties

Defendant

Teva Pharmaceutical Industries Ltd. Operating Company

Represented By

0 Attorneys Listed
No attorneys available

Teva Pharmaceuticals USA, Inc. Operating Company

Represented By

8 Attorneys Listed

Scott J. Bornstein

Email: bornsteins@gtlaw.com

Richard C. Pettus

Email: pettusr@gtlaw.com

Justin A. MacLean

Email: macleanj@gtlaw.com

Jonathan D. Ball

Email: ballj@gtlaw.com

Andrew Russell

Shaw Keller LLP

Tel: +1 (302) 298-0704

1105 North Market St., 12th Floor, I. M. Pei Building

Allan A. Kassenoff

Email: kassenoffa@gtlaw.com

Karen Elizabeth Keller

Shaw Keller LLP

Tel: +1 (302) 298-0700

1105 North Market Street, 12th Floor, Wilmington, DE 19801

John W. Shaw

Shaw Keller LLP

Tel: +1 (302) 298-0701

I.M. Pei Building, 1105 North Market Street

Plaintiff

Meda Pharmaceuticals Inc. Operating Company

Represented By

12 Attorneys Listed

Uma N. Everett

Email: ueverett@sternekessler.com

Selena E. Molina

Delaware Court of Chancery

Tel: +1 (302) 421-6829

Delaware Court of Chancery, 500 North King Street

Rami Bardenstein

UNDELIVERABLE 12/28/2016

UNDELIVERABLE 12/28/2016

Mark F. Evens

Email: mevens@skgf.com

Joshua I. Miller

Email: jmiller@skgf.com

Josephine J. Kim

Email: joskim@sternekessler.com

Arun John Mohan

Schiff Hardin LLP

Tel: +1 (212) 745-9536
Fax: +1 (212) 753-5044

666 Fifth Avenue, Suite 1700, New York, NY 10103

Adam C. LaRock

Email: alarock@sternekessler.com

Frederick L. Cottrell , III

Richards, Layton & Finger, PA

Tel: +1 (302) 658-6541

Richards, Layton & Finger, PA, One Rodney Square

Steven J. Balick

Ashby & Geddes

Tel: +1 (302) 654-1888
Fax: +1 (302) 654-2067

Ashby & Geddes, 500 Delaware Avenue, 8th Floor

John G. Day

Ashby & Geddes

Tel: +1 (302) 654-1888

Ashby & Geddes, 500 Delaware Avenue, 8th Floor

Andrew Colin Mayo

Ashby & Geddes

Tel: +1 (302) 654-1888

Ashby & Geddes, 500 Delaware Avenue, 8th Floor

Counter Defendant

Cipla Ltd. Operating Company

Represented By

6 Attorneys Listed

Selena E. Molina

Delaware Court of Chancery

Tel: +1 (302) 421-6829

Delaware Court of Chancery, 500 North King Street

Arun John Mohan

Schiff Hardin LLP

Tel: +1 (212) 745-9536
Fax: +1 (212) 753-5044

666 Fifth Avenue, Suite 1700, New York, NY 10103

Frederick L. Cottrell , III

Richards, Layton & Finger, PA

Tel: +1 (302) 658-6541

Richards, Layton & Finger, PA, One Rodney Square

Steven J. Balick

Ashby & Geddes

Tel: +1 (302) 654-1888
Fax: +1 (302) 654-2067

Ashby & Geddes, 500 Delaware Avenue, 8th Floor

John G. Day

Ashby & Geddes

Tel: +1 (302) 654-1888

Ashby & Geddes, 500 Delaware Avenue, 8th Floor

Andrew Colin Mayo

Ashby & Geddes

Tel: +1 (302) 654-1888

Ashby & Geddes, 500 Delaware Avenue, 8th Floor

Court & Judges

Court

District Court, D. Delaware (ded)

Global Patent Family Cross-Litigation Radar

CasLoc 360° Radar 5 Family Members

Multi-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions

🇺🇸
U.S. District Courts 5 proceedings
🏛️
USPTO PTAB Trials 5 proceedings
🇪🇺
Unified Patent Court (UPC) Counterparts in force
🇩🇪
European Patent Office (EPO) Counterparts in force
Worldwide Family Members (5): GB 🇺🇸 US 🌐 PCT
Parallel Proceedings Across Jurisdictions (10 found):
PTAB: 5 U.S. Courts: 5
USPTO PTAB Trial 2020-01-31
IPR2020-00370

GlaxoSmithKline Consumer Healthcare Holdings (US) LLC v. Cipla Limited et al.

U.S. Continuation Sibling (9259428)
Status: Institution Denied
USPTO PTAB Trial 2020-01-31
IPR2020-00369

GlaxoSmithKline Consumer Healthcare Holdings (US) LLC v. Cipla Limited et al.

Asserted Patent
Status: Institution Denied
USPTO PTAB Trial 2020-01-31
IPR2020-00368

GlaxoSmithKline Consumer Healthcare Holdings (US) LLC v. Cipla Limited et al.

U.S. Continuation Sibling (8163723)
Status: Institution Denied
USPTO PTAB Trial 2017-02-02
IPR2017-00807

Argentum Pharmaceuticals LLC v. Cipla Limited

Asserted Patent
Status: Terminated-Settled
USPTO PTAB Trial 2014-05-07
IPR2014-00731

Impax Laboratories, Inc. v. Meda Pharmaceuticals Inc.

U.S. Continuation Sibling (8071073)
Status: Institution Denied
U.S. District Court 2017-04-19
1:17-cv-00439

Meda Pharmaceuticals Inc. v. Akorn, Inc.

U.S. Family Sibling (["US8071073", "US8518919"])
Status: DED
U.S. District Court 2016-09-09
1:16-cv-00794

Meda Pharmaceuticals Inc. v. Perrigo UK FINCO Limited Partnership

Asserted Patent
Status: DED
U.S. District Court 2015-07-17
1:15-cv-00617

Meda Pharmaceuticals Inc. v. Amneal Pharmaceuticals LLC

U.S. Family Sibling (["US8071073", "US8518919"])
Status: DED
U.S. District Court 2015-06-17
1:15-cv-00510

Meda Pharmaceuticals Inc. v. Amneal Pharmaceuticals LLC

U.S. Family Sibling (["US8071073", "US8518919"])
Status: DED
U.S. District Court 2012-01-19
3:12-cv-00361

MEDA PHARMACEUTICALS INC. v. APOTEX INC.

U.S. Family Sibling (["US8071073"])
Status: NJD
Stay ahead of cross-border rulings. Subscribe for free automated docket alerts across U.S. Courts, PTAB, UPC, and EPO.

Patents Involved

10 Patents

There are 10 patents involved in this case.

Patent Asset Filing & Issue Date Expiration & Term Status External Links
US8163723
Combination of azelastine and steroids
Filed: 2010-09-10
Issued: 2012-04-24
Expired (Term Ended)
Expires: 2023-08-29
US8168620
Combination of azelastine and steroids
Filed: 2003-06-13
Issued: 2012-05-01
Expired (Term Ended) +987d PTA
Expires: 2026-02-24
US9259428
Combination of azelastine and fluticasone for nasal administration
Filed: 2015-03-18
Issued: 2016-02-16
Active (8.3 yrs remaining)
Expires: 2035-03-18
US5164194
Azelastine containing medicaments
Filed: 1990-07-12
Issued: 1992-11-17
Expired (Term Ended) +112d PTA
Expires: 2010-11-01
US8071073
Compositions comprising azelastine and methods of use thereof
Filed: 2005-11-22
Issued: 2011-12-06
Active (1.5 yrs remaining) +925d PTA
Expires: 2028-06-04

Patent Enforceability & Injunction Risk Assessment

Statutory Analysis
Injunction Viability (35 U.S.C. § 283) Statutorily Barred

Statutorily Barred — Patent expired. Under 35 U.S.C. § 283, injunctive relief is barred.

Terminal Disclaimer & Cellect Risk Low Risk

Standard Statutory Term — No obviousness-type double patenting noted.

Damages Lookback Horizon 6-Yr Max Lookback

Under 35 U.S.C. § 286, damages cannot accrue for infringement prior to 6 years before filing. 4th & 8th Year Maintenance Fees Paid (12th Year Window Upcoming).

Procedural Motions & Interlocutory Orders

Motion Intelligence

Total Motions

42

Dispositive

0

Granted

0

Denied

2

Pending / Review

37

Motions by Category

Claim Construction / Markman Filing 32 Procedural / Extension Motion 10

Key Dispositive Motions & Rulings

Claim Construction / Markman Filing Pending / Under Review
RESPONSE to Order re 113 Memorandum and Order [DEFENDANT TEVA PHARMACEUTICALS USA, INC.'S SUPPLEMENTAL CLAIM CONSTRUCTION BRIEF REGARDING THE PHRASE "FROM 0.001...
Entry #115 • 2016-12-14 Document →
Claim Construction / Markman Filing Pending / Under Review
Official Transcript of Claim Construction Hearing held on December 2, 2016 before Chief Judge Leonard P. Stark. Court Reporter Brian Gaffigan, Telephone (302) 5...
Entry #114 • 2016-12-11 Document →
Claim Construction / Markman Filing Pending
Markman Hearing
Entry #— • 2016-12-02
Claim Construction / Markman Filing Pending / Under Review
Letter to The Honorable Chief Judge Leonard P. Stark from Frederick L. Cottrell, III regarding enclosing additional exhibits to the Amended Joint Claim Construc...
Entry #109 • 2016-11-23 Document →
Claim Construction / Markman Filing Pending / Under Review
NOTICE of filing the following Non-Paper material(s) in multi media format: CD containing portions of the intrinsic record cited in the Amended Joint Claim Cons...
Entry #103 • 2016-11-14 Document →
Procedural / Extension Motion Denied
MEMORANDUM ORDER re 61 MOTION for Leave to File Second Amended Complaint filed by Meda Pharmaceuticals Inc., Cipla Ltd. is DENIED. Signed by Judge Le...
Entry #104 • 2016-11-14 Document →

Docket Entries

(162 total)
Pleading / Complaint

COMPLAINT filed against Teva Pharmaceutical Industries Ltd., Teva Pharmaceuticals USA, Inc. - Magistrate Consent Notice to Pltf. ( Filing fee $ 400, receipt number 24030.) - filed by Meda Pharmaceuticals Inc., Cipla Ltd.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Acknowledgement of Consent Form, # 4 Civil Cover Sheet)(sar) (Entered: 09/09/2015)

Entry #1 • 2015-09-08
1

Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (sar) (Entered: 09/09/2015)

Entry #2 • 2015-09-08
1

Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 7/30/15. Date of Expiration of Patent: 8/29/23 2/24/26.Thirty Month Stay Deadline: 1/30/2018. (sar) (Entered: 09/09/2015)

Entry #3 • 2015-09-08
1

Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 8,163,723; 8,168,620;. (sar) (Entered: 09/09/2015)

Entry #4 • 2015-09-08
1

Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Meda AB for Cipla Ltd., Meda Pharmaceuticals Inc. filed by Cipla Ltd., Meda Pharmaceuticals Inc.. (sar) (Entered: 09/09/2015)

Entry #5 • 2015-09-08
1

Track Case Updates

Automated email notifications for new filings & decisions

Identifier: •

Free service • 1-click unsubscribe anytime • Powered by CasLoc